{"id":802388,"date":"2026-04-15T14:11:01","date_gmt":"2026-04-15T14:11:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=802388"},"modified":"2026-04-15T14:11:01","modified_gmt":"2026-04-15T14:11:01","slug":"pointofcare-molecular-diagnostics-market-to-reach-709-billion-by-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pointofcare-molecular-diagnostics-market-to-reach-709-billion-by-2030_802388.html","title":{"rendered":"Point-of-Care Molecular Diagnostics Market to Reach $7.09 Billion by 2030"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1776236907.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Point-of-Care Molecular Diagnostics Market to Reach $7.09 Billion by 2030\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/04\/1776236907.jpg\" alt=\"Point-of-Care Molecular Diagnostics Market to Reach $7.09 Billion by 2030\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Point-of-Care Molecular Diagnostics Market by Product &#038; Service (Assays, Instruments, Software), Technology (RT-PCR, INAAT), Sample Type (Blood, Urine), Application (STD, HAI, Hepatitis, Cancer), and End User (Hospitals, Clinics) &#8211; Global Forecast to 2030.<\/div>\n<p style=\"text-align: justify;\"><strong>According to MarketsandMarkets&trade;, <\/strong> the global <strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/point-of-care-molecular-diagnostic-market-143524127.html?utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">Point-of-Care Molecular Diagnostics Market<\/a><\/strong> is projected to grow from <strong>USD 4.30 billion in 2025 to USD 7.09 billion by 2030<\/strong>, registering a <strong>CAGR of 10.5%<\/strong> during the forecast period. Market growth is driven by the increasing demand for rapid and accurate diagnostic solutions, particularly in emergency, remote, and decentralized healthcare settings.<\/p>\n<p style=\"text-align: justify;\"><strong>Download PDF Brochure: <a rel=\"nofollow\" name=\"www_marketsandmarkets_com_pdfdownlo\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=143524127&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=143524127<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Browse<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>355 <\/strong>Market Data Tables<\/li>\n<li><strong>55 <\/strong>Figures<\/li>\n<li><strong>327 <\/strong>Pages and in-depth TOC on<strong> &#8220;<\/strong> <strong>Point of Care Molecular Diagnostics Market <strong>&#8211; Global Forecast to 2030&rdquo;.<\/strong><\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The rising prevalence of infectious diseases&mdash;including respiratory infections, sexually transmitted diseases (STDs), and gastrointestinal illnesses&mdash;is significantly boosting the demand for timely diagnosis and treatment. Additionally, growing awareness of early disease detection and its impact on patient outcomes is accelerating the adoption of point-of-care molecular diagnostics across diverse healthcare environments. Continuous investments in R&amp;D are further driving innovation in compact, high-performance platforms and expanding test menus, making advanced molecular diagnostics more accessible at the point of care.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Market Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">By technology, the <strong>RT-PCR segment<\/strong> accounted for the largest share of the market in 2024. Its high sensitivity, specificity, and rapid turnaround time have led to widespread adoption across hospitals and decentralized healthcare settings. The integration of compact, user-friendly RT-PCR systems into point-of-care environments has significantly enhanced diagnostic efficiency. Ongoing advancements aimed at improving workflow automation and result accuracy are expected to sustain the segment&rsquo;s leadership.<\/p>\n<p style=\"text-align: justify;\"><strong>End User Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">By end user, the <strong>hospitals segment<\/strong> held the largest share of the market in 2024. This dominance is attributed to high patient volumes and the critical need for rapid and accurate diagnostic solutions in emergency and intensive care settings. The growing burden of infectious diseases and the demand for real-time clinical decision-making are driving increased adoption of point-of-care molecular diagnostics in hospitals. Furthermore, investments in decentralized testing capabilities are helping healthcare providers streamline workflows and reduce reliance on centralized laboratories.<\/p>\n<p style=\"text-align: justify;\"><strong>Regional Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>North America<\/strong> accounted for the largest share of the point-of-care molecular diagnostics market in 2024. The region&rsquo;s leadership is supported by advanced healthcare infrastructure, strong adoption of innovative diagnostic technologies, and the presence of skilled healthcare professionals. The integration of point-of-care testing into routine clinical workflows and increasing access to advanced diagnostic tools continue to drive market growth across the region.<\/p>\n<p style=\"text-align: justify;\"><strong>Request Sample Pages: <a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=143524127&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=143524127<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Competitive Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">The point-of-care molecular diagnostics market is highly competitive, with key players focusing on innovation, product development, and strategic collaborations. Leading companies in this market include Danaher Corporation, bioM&eacute;rieux, F. Hoffmann-La Roche Ltd., Abbott Laboratories, QIAGEN N.V., QuidelOrtho Corporation, Co-Diagnostics, Inc., Biocartis Group NV, SD Biosensor, Inc., genedrive plc, Binx Health, Inc., Molbio Diagnostics Pvt. Ltd., Genomadix, Visby Medical, Inc., QuantuMDx Group Ltd., DetectaChem, Labsystems Diagnostics Oy, Akonni Biosystems, Inc., Ubiquitome Limited, Credo Diagnostics Biomedical Pte. Ltd., OpGen, Inc., Nuclein, LLC, Genes2Me, Axxin, and Huwel Lifesciences.<\/p>\n<p style=\"text-align: justify;\">As healthcare systems increasingly shift toward decentralized, patient-centric care models, the point-of-care molecular diagnostics market is expected to witness robust growth, driven by technological innovation, expanding disease burden, and the need for faster, more accessible diagnostic solutions.<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=703&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">In Vitro Diagnostics Market<\/a> &#8211; Global Forecast to 2030<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=106829185&amp;utm_source=abnewswire.com&amp;utm_medium=referral&amp;utm_campaign=paidpr\">Point of Care Diagnostics Market<\/a> &#8211; Global Forecast to 2029<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_145966.html\" rel=\"nofollow\">MarketsandMarkets\u2122 Research Private Ltd.<\/a><br \/><strong>Contact Person:<\/strong> Mr. Rohan Salgarkar<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pointofcare-molecular-diagnostics-market-to-reach-709-billion-by-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 18886006441<br \/><strong>Address:<\/strong>1615 South Congress Ave.  Suite 103, Delray Beach, FL 33445<br \/><strong>City:<\/strong> Florida<br \/><strong>State:<\/strong> Florida<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/point-of-care-molecular-diagnostic-market-143524127.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/point-of-care-molecular-diagnostic-market-143524127.html<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pointofcare-molecular-diagnostics-market-to-reach-709-billion-by-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Point-of-Care Molecular Diagnostics Market by Product &#038; Service (Assays, Instruments, Software), Technology (RT-PCR, INAAT), Sample Type (Blood, Urine), Application (STD, HAI, Hepatitis, Cancer), and End User (Hospitals, Clinics) &#8211; Global Forecast to 2030. According to MarketsandMarkets&trade;, the global Point-of-Care Molecular &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pointofcare-molecular-diagnostics-market-to-reach-709-billion-by-2030_802388.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,411,404],"tags":[],"class_list":["post-802388","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Technology","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/802388","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=802388"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/802388\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=802388"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=802388"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=802388"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}